The GW VRU participated in a Phase 2 randomized clinical trial that evaluated the safety and the immunogenicity of two doses of the MVA-BN vaccine for mpox that were one-fifth and one-tenth the standard dose. The team is excited to announce that the clinical findings have been reported and found that the lower doses were safe, well-tolerated, and produced an immune response in comparison to the standard dose.
Results show safety and immunogenicity of fractional doses of the MVA-BN mpox vaccine
Latest News
This was a phase 1, double-blind trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever.
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…